Literature DB >> 35604239

Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report.

Birao Fan, Mingyue Wang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35604239      PMCID： PMC9558324          DOI： 10.2340/actadv.v102.1378

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  15 in total

1.  Treatment of Mucous Membrane Pemphigoid With Janus Kinase Inhibitor Baricitinib.

Authors:  Stephanie Sarny; Miriam Hucke; Yosuf El-Shabrawi
Journal:  JAMA Ophthalmol       Date:  2018-12-01       Impact factor: 7.389

Review 2.  Obliterative bronchiolitis.

Authors:  Alan F Barker; Anne Bergeron; William N Rom; Marshall I Hertz
Journal:  N Engl J Med       Date:  2014-05-08       Impact factor: 91.245

3.  Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults.

Authors:  Elise Ouedraogo; Jeremy Gottlieb; Adèle de Masson; Clémence Lepelletier; Marie Jachiet; Camille Salle de Chou; Lionel Galicier; Martine Bagot; Sylvie Chevret; Jean-David Bouaziz
Journal:  J Am Acad Dermatol       Date:  2019-04-10       Impact factor: 11.527

Review 4.  Current and future status of JAK inhibitors.

Authors:  Donal P McLornan; Janet E Pope; Jason Gotlib; Claire N Harrison
Journal:  Lancet       Date:  2021-08-28       Impact factor: 79.321

Review 5.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

6.  Ruxolitinib-associated infections: A systematic review and meta-analysis.

Authors:  Federico Lussana; Marco Cattaneo; Alessandro Rambaldi; Alessandro Squizzato
Journal:  Am J Hematol       Date:  2017-12-04       Impact factor: 10.047

7.  Tofacitinib for refractory ocular mucous membrane pemphigoid.

Authors:  Hayley James; Grace L Paley; Richard Brasington; Philip L Custer; Todd P Margolis; Michael A Paley
Journal:  Am J Ophthalmol Case Rep       Date:  2021-04-21

8.  Features and Risk Factors for Paraneoplastic Autoimmune Multiorgan Syndrome in 145 Chinese Patients.

Authors:  Mingyue Wang; Furong Li; Xintong Wang; Xue Wang; Rui Wang; Yinmo Yang; Jian Li; Shijie Zhang; Weiming Huang; Yujun Dong; Xiangdong Mu; Ting Li; Kaiwen Ni; Xixue Chen; Xuejun Zhu
Journal:  Acta Derm Venereol       Date:  2020-11-04       Impact factor: 3.875

9.  Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement.

Authors:  Martina Kaurinovic; Konstantina Delli; Ana-Mae E Jonk; Anouschka Biswana; Carin L E Hazenberg; Goda Choi; Marco R de Groot; Linde M Morsink; Arjan Vissink; Mar Bellido
Journal:  Clin Oral Investig       Date:  2022-02-16       Impact factor: 3.606

10.  Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.

Authors:  Dong Wang; Yin Liu; Xiaoxuan Lai; Jia Chen; Qiao Cheng; Xiao Ma; Zhihong Lin; Depei Wu; Yang Xu
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.